Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
ID: 357651Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357651

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-346.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed), aimed at advancing innovative bioengineering solutions to address cancer and other biomedical challenges. This funding opportunity encourages projects that demonstrate the feasibility and potential utility of novel capabilities to enhance biomedical research, clinical care delivery, and accessibility, while specifically discouraging clinical trial proposals. Eligible applicants include a diverse range of institutions such as higher education entities, nonprofits, for-profit organizations, and foreign entities, with a funding cap of $275,000 available over a two-year period. Interested applicants can find more information and submission guidelines on the NIH website, with applications due by January 7, 2028. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-346-Full-Announcement.html
    PAR-25-346.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), invites applications for the Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21), aimed at advancing bioengineering solutions applicable to cancer and other biomedical challenges. This funding opportunity, reissuing the PAR-22-090 notice, supports projects that demonstrate feasibility and potential utility of novel capabilities to improve biomedical research, clinical care delivery, and accessibility. Eligible applicants include various higher education institutions, nonprofits, for-profit organizations, and foreign entities, with a funding cap of $275,000 over two years. The initiative specifically discourages clinical trial proposals. The application process is electronic, requiring adherence to strict submission guidelines via Grants.gov. Key review criteria focus on the importance and innovation of proposed research, rigor and feasibility of the approach, and the expertise of the research team. This opportunity encourages multidisciplinary collaborations between bioengineers and biomedical researchers, fostering innovative solutions and technologies to address complex health issues. The overarching goal is to contribute significantly to cancer risk identification, prevention, and the overall advancement of health research.
    Similar Opportunities
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering funding through the Exploratory/Developmental Bioengineering Research Grants (EBRG) program, aimed at enhancing biomedical research and clinical care. This initiative encourages innovative applications that focus on developing new capabilities to address challenges in biomedical, preclinical, or clinical settings, with an emphasis on feasibility testing and novel methodologies. The program is particularly significant for advancing cancer research through innovative bioengineering approaches, welcoming proposals from a diverse range of eligible applicants, including universities, nonprofits, and small businesses, especially those representing underrepresented groups. The maximum budget for applicants is $275,000 over two years, with applications due by January 7, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-321.html.
    NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) to support innovative early-stage research projects that may lead to significant advancements in biomedical, behavioral, or clinical fields. This grant is designed to encourage high-risk, high-reward research, providing funding for projects that are distinct from traditional R01 grants, with a maximum budget of $275,000 over a two-year period, and no more than $200,000 in any single year. Eligible applicants include a wide range of organizations such as educational institutions, nonprofit organizations, and tribal governments, with applications undergoing a rigorous peer review process to assess their innovation and feasibility. Interested parties should note that the application submission period begins on January 16, 2025, with the opportunity closing on January 7, 2028; for further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Bioengineering Research Grants (BRG) under the R01 Clinical Trial Optional program, aimed at fostering collaborations between life and physical sciences to address biomedical challenges. The grants encourage multidisciplinary bioengineering approaches that integrate and accelerate the adoption of innovative tools and methods for research or clinical problems in basic, translational, or clinical science. This funding opportunity is particularly significant for small teams looking to enhance understanding and solve issues in biological and clinical sciences. Interested applicants can reach out to Dr. Miguel R. Ossandon at ossandom@mail.nih.gov or by phone at 240-276-5714, with an estimated award date of December 1, 2026, and a closing date for applications on February 5, 2026. The program anticipates awarding approximately 50 grants, with no cost-sharing or matching requirements.
    NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required) to support innovative research projects in the early stages that can lead to significant advancements in biomedical, behavioral, and clinical research. This funding opportunity requires applicants to propose at least one clinical trial and is aimed at addressing critical gaps in knowledge within the scientific missions of participating NIH Institutes and Centers. Eligible applicants include a diverse range of organizations, such as higher education institutions, nonprofits, and foreign entities, with a total project period limited to two years and a budget of up to $275,000. The application period opens on January 16, 2025, and closes on January 8, 2028; interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory research grants (R21) aimed at developing innovative technologies in biomedical research. This initiative seeks applications that propose high-risk, high-reward projects focused on technology development without existing proof of concept, specifically excluding clinical trials. The funding amount is capped at $275,000 in direct costs over two years, with a maximum of $200,000 available in any single year. Interested applicants, including higher education institutions and nonprofit organizations, must adhere to submission guidelines and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. The application deadline is January 7, 2028.
    Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Exploratory Grants in Cancer Control through the R21 Clinical Trial Optional mechanism, aimed at advancing innovative research in cancer control. This funding opportunity encourages applications focused on behavioral modification, screening, and understanding the etiological factors of cancer, with the goal of developing novel methodologies and tools that can significantly impact population-based cancer research. Grants of up to $275,000 are available for projects lasting up to two years, with application deadlines beginning January 16, 2025, and continuing through 2028. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PA-25-253.html.
    NIH Exploratory/Developmental Research Project Grant (Parent R21 Basic Experimental Studies with Humans Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Project Grant (Parent R21 Basic Experimental Studies with Humans Required) to support innovative research projects that involve basic experimental studies with human participants. This funding opportunity aims to foster groundbreaking research strategies that can lead to significant advancements in biomedical, behavioral, or clinical research, particularly in understanding fundamental phenomena without immediate application in mind. Grants may be awarded for a total project period of up to two years, with budgets capped at $275,000, and applications are encouraged from a diverse range of eligible applicants, including historically black colleges and universities, faith-based organizations, and other institutions. Interested parties should note that the application deadline is January 7, 2028, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the "Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research" (R21 Clinical Trial Not Allowed). This funding opportunity aims to enhance diversity among early-stage and junior investigators in cancer research, particularly from groups that are underrepresented in the biomedical, behavioral, clinical, and social sciences. The initiative encourages innovative studies in cancer biology, with a maximum funding amount of $275,000 available over a two-year period, and applications must demonstrate scientific merit and innovation. The application window opens on May 17, 2024, with the first awards expected to be made in June 2024; interested applicants can find more information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Trailblazer Award for New and Early Stage Investigators, a federal grant aimed at fostering innovative biomedical research that integrates engineering with life sciences. This funding opportunity, under the R21 Exploratory/Developmental Research Grant mechanism, allows for up to $400,000 in direct costs over a three-year period for projects that require minimal preliminary data, encouraging high-risk, high-reward research. The initiative is designed to enhance diversity within the research community and is open to a wide range of eligible applicants, including various educational institutions and community organizations. Interested parties should note that the application submission period opens on January 16, 2025, and closes on January 8, 2026; for further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Exploratory/Developmental Research Grants (R21) focused on the Ethical, Legal, and Social Implications (ELSI) of human genetics and genomics. This initiative invites applications that utilize various methodologies, including qualitative and quantitative research, to explore ELSI issues and foster interdisciplinary collaboration while informing policy on equitable genomic research applications across diverse populations. The program aims to address critical areas such as cancer disparities and community engagement in genomics, recognizing the transformative potential of genomics in healthcare while assessing ethical and social challenges, particularly for underrepresented communities. Applicants may request up to $275,000 for projects lasting up to three years, with applications due between January 20, 2025, and November 19, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.